Immunomodulators
Cross-source consensus on Immunomodulators from 1 sources and 4 claims.
1 sources · 4 claims
Risks & contraindications
Evidence quality
Where it comes from
Highlighted claims
- A total of 141 FDA-approved immunomodulators were evaluated in the VigiBase analysis. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- Twenty immunomodulators remained significantly associated with atrial fibrillation over-reporting after adjustment and Bonferroni correction. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- The study evaluated FDA-approved immunomodulators in ATC classes L03 and L04 with at least one VigiBase report. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review
- The twenty significant immunomodulators accounted for about half of all atrial fibrillation cases in the primary immunomodulator-reporting population. — Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review